Breaking Finance News

Citigroup reiterated GlaxoSmithKline PLC (LON:GSK) to Buy in a report released today.

Citigroup has reiterated GlaxoSmithKline PLC (LON:GSK) to Buy in a report released on 9/23/2016.

Yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.24% higher at 1,644.50GBX. The company’s 50-day moving average is 1,652.33GBX and its 200-day moving average is 1,532.89GBX. The last closing price is up 7.84% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,642,219 shares of GSK traded hands, down from an average trading volume of 8,755,900

Recent Performance Chart

GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline PLC has 52 week low of 1,227.50GBX and a 52 week high of 1,716.50GBX with a PE ratio of 2,755.00 and has a market capitalization of 0 GBX.

In addition to Citigroup reporting its target price, a total of 24 firms have reported on the stock. The consensus target price is 1,577.33GBX with 3 firms rating the stock a strong buy, six analysts rating the company a buy, seventeen analysts rating the company a hold, two analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

More About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *